Profile: Array Biopharma Inc (ARRY.O)
17 Nov 2017
Array BioPharma Inc. (Array), incorporated on February 6, 1998, is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company has approximately five registration studies that are advancing. Its programs include approximately three cancer drugs, binimetinib (MEK162), encorafenib (LGX818) and selumetinib (partnered with AstraZeneca). Binimetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial; encorafenib is a BRAF inhibitor for cancer, which is in Phase III trial, and selumetinib is a MEK inhibitor for cancer, which is in Phase III trial.
The Company's advanced clinical stage drugs include Filanesib, which is a kinesin spindle protein (KSP) inhibitor for multiple myeloma (MM) under Phase II trial; ARRY-797, which is a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy under Phase II trial, and ARRY-382, which is a colony stimulating factor 1 receptor (CSF1R) inhibitor for cancer under Phase I trial. The Company's drug candidates also include ASC08/Danoprevir, which is a protease inhibitor for Hepatitis C virus under Phase III trial; ASLAN001/Varlitinib, which is an Pan-HER inhibitor for gastric or breast cancer under Phase II trial; Ipatasertib/GDC-0068, which is an AKT inhibitor for cancer under Phase II trial; Motolimod/VTX-2337, which is a Toll-like receptor for cancer under Phase II trial; Prexasertib/LY2606368, which is a checkpoint kinase 1 (Chk-1) inhibitor for cancer under Phase II trial; LOXO-101, which is a PanTrk inhibitor for cancer under in Phase II trial; ONT-380/ARRY-380, which is a human epidermal growth factor receptor 2 (HER2) inhibitor for breast cancer under Phase II trial; GDC-0575, which is a Chk-1 inhibitor for cancer that is in Phase Ib trial, and GDC-0994, which is a extracellular regulated kinase (ERK) inhibitor for cancer under Phase I trial.
The Company's binimetinib and encorafenib are being studied in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma, and BEACON CRC trial (binimetinib, encorafenib and cetuximab combined to treat BRAF-mutant colorectal cancer) to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). The Company has a portfolio of owned and partnered preclinical drug discovery programs.
Array Biopharma Inc
3200 Walnut St
BOULDER CO 80301-2514
Company Web Links
- BRIEF-Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
- BRIEF-ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22
- BRIEF-Array Biopharma announces proposed public offering of common stock
- BRIEF-Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma
- BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel